EDN1 and Schnyder corneal dystrophy: Our results provide evidence that ET-1 is a novel regulator of MHC promoter activity and suggest that ET-1 receptor blockade represents an important therapeutic approach to improve the immune and inflammatory responses and vascular complications in SCD.